A randomized controlled trial of Japanese patients with obsessive–compulsive disorder—effectiveness of behavior therapy and fluvoxamine
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background: The aim of this study was to confirm and compare the efficacy of fluvoxamine (the only licensed SSRI for treatment for OCD in Japan) and behavior therapy in treating Japanese patients with OCD. In addition, we investigated predictors of these treatments. Methods: Thirty-one outpatients meeting the DSM-III-R criteria for OCD without any axis I disorder were randomly assigned to one of three treatment conditions: BT (behavior therapy ± pill placebo), FLV [autogenic training (a psychological placebo for OCD) ± fluvoxamine] and control group [autogenic training (psychological placebo) ± pill placebo] for 12 weeks of treatment. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and the Clinical Global Impression-Improvement Scale (CGI-I) were administered blindly at baseline and week 4, 8 and 12. Results: Twenty-eight patients completed this study. Patients in the BT and FLV groups showed significantly more improvement than those in the control group in the mean score of total Y-BOCS; moreover, the BT group showed significantly more reduction in total Y-BOCS score at the end of treatment than the FLV group (BT > FLV, p < 0.01). Patients with lower baseline total Y-BOCS, past history of a major depressive episode and absence of cleaning compulsion improved more with fluvoxamine. Conclusions: We confirmed the effectiveness of behavior therapy and fluvoxamine for Japanese patients with OCD. Behavior therapy improved the condition of OCD patients more than fluvoxamine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stress Management was less efficacious than ERP when combined with pill placebo in a study in Japan (Nakatani et al., 2005), and less efficacious than ERP when added to ongoing medication treatment in patients who had shown partial response (Simpson et al., 2008b), and when added to substance abuse treatment in a therapeutic community for patients with comorbid substance use disorders (Fals-Stewar”
From An update on the efficacy of psychological treatments for obsessive-compulsive disorder in adults (2013) · cites this paper as Nakatani et al., 2005
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982 · cited 1×
“were used as the principal measures. ‘Responders’ were defined as patients who showed at least 35p reduction from baseline total Y-BOCS score and were assessed as ‘much improved’ or ‘very much improved’ according to the CGI-I. Other treatment procedures were added to the regimen of ‘nonresponders’ and treatment was co…”
MethodThe Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency
Kim, S. W., Dysken, M. W., Pheley, A. M., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,359
Mataix-Cols, D., Rauch, S. L., Manzo, P. A., Jenike, M. A., & Baer, L. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1409 · Cited by 716
Mataix-Cols, D., Marks, I. M., Greist, J. H., Kobak, K. A., & Baer, L. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000064812 · Cited by 499
A Review of the Efficacy of Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder
Pigott, T. A., & Seay, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0206 · Cited by 454
Franklin, M. E., Abramowitz, J. S., Kozak, M. J., Levitt, J. T., & Foa, E. B. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.4.594 · Cited by 387 · cited 1×
“On the other hand, the treatment outcome of behavior therapy in general has been satisfactory when applied appropriately [”
Background
Research works printed but not linked: 1
- 10.1037%2F%2F0022-006X.68.4.594 · doi:10.1037//0022-006x.68.4.594 · Paper page
Cited by
Abramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
“Fluvoxamine was and found to be superior to placebo in DBPC studies (Goodman et al. 1989b, 1996; Hohagen et al. 1998; Nakatani et al. 2005) and in clomipramine-controlled trials (Milanfranchi et al.”
BackgroundResultÖst, L.-G., Havnen, A., Hansen, B., & Kvale, G. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.06.003 · Cited by 655
“(2008), nor Olatunji et al. (2013) found that gender affected the ES significantly.”
BackgroundResultCuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. (2013) · World Psychiatry · doi:10.1002/wps.20038 · Cited by 540
“Nakatani et al (73) OCD BT (n510) SSRI (n510) 2 2 1 2 Japan”
Psychological treatment of obsessive–compulsive disorder: A meta-analysis
Rosa-Alcázar, A. I., Sánchez-Meca, J., Gómez-Conesa, A., & Marín-Martínez, F. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2008.07.001 · Cited by 444
Skapinakis, P., Caldwell, D. M., Hollingworth, W., Bryden, P., Fineberg, N. A., Salkovskis, P., Welton, N. J., Baxter, H., Kessler, D., Churchill, R., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30069-4 · Cited by 407
Soomro, G. M., Altman, D. G., Rajagopal, S., & Oakley Browne, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001765.pub3 · Cited by 342
Nakao, T., Nakagawa, A., Yoshiura, T., Nakatani, E., Nabeyama, M., Yoshizato, C., Kudoh, A., Tada, K., Yoshioka, K., Kawamoto, M., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.039 · Cited by 307
Self-citationReid, J. E., Laws, K. R., Drummond, L., Vismara, M., Grancini, B., Mpavaenda, D., & Fineberg, N. A. (2021) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2021.152223 · Cited by 266
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
“Placebo-controlled studies in OCD patients consistently associated fluvoxamine administration (dosage range 100300 mg/day) with treatment response [43-47], although with some exceptions [48-52].”
BackgroundPharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213
Knopp, J., Knowles, S., Bee, P., Lovell, K., & Bower, P. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.08.008 · Cited by 164
“Uncertain Nakatani et al. (2005) ?”
Minority Participation in Randomized Controlled Trials for Obsessive-Compulsive Disorder
(2010) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.11.004 · Cited by 157
“Most randomized trials of OCD patients have been conducted in North America and Europe (Williams, Powers, & Foa, in press), with scattered reports from a handful of other areas, most notably Japan (Nakatani et al., 2005), India (Mehta, 1990), and Brazil (Cordioli et al.”
Nabeyama, M., Nakagawa, A., Yoshiura, T., Nakao, T., Nakatani, E., Togao, O., Yoshizato, C., Yoshioka, K., Tomita, M., & Kanba, S. (2008) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2007.11.001 · Cited by 137
“All participants with OCD were outpatients of the Department of Neuropsychiatry of Kyushu University Hospital who were involved in a randomized controlled trial of behavior therapy (Nakatani et al., 2005).”
MethodSelf-citationSkapinakis, P., Caldwell, D., Hollingworth, W., Bryden, P., Fineberg, N., Salkovskis, P., Welton, N., Baxter, H., Kessler, D., Churchill, R., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20430 · Cited by 134
Remote treatment of obsessive-compulsive disorder: A randomized controlled trial
Wootton, B. M., Dear, B. F., Johnston, L., Terides, M. D., & Titov, N. (2013) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2013.07.002 · Cited by 125
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Where does obsessive–compulsive disorder belong in DSM-V?
Storch, E. A., Abramowitz, J., & Goodman, W. K. (2008) · Depression and Anxiety · doi:10.1002/da.20488 · Cited by 122
“Moreover, treatment based on this model—cognitive-behavioral therapy (CBT)—is the most effective individual treatment available for OCD [e.g., Foa et al., 2005; Nakatani et al., 2005].”
MethodRomanelli, R. J., Wu, F. M., Gamba, R., Mojtabai, R., & Segal, J. B. (2014) · Depression and Anxiety · doi:10.1002/da.22232 · Cited by 121
“In the analysis by Cuipjer et al., the authors included two studies that were excluded from our analysis due to the evaluation of EMDR[37] and meta-cognitive therapy,[38] whereas the other studies used ExRP/CBT.[28, 29, 31, 32] In the analysis by Roshanaei-Moghaddam et al., one RCT was conducted in inpatients and was…”
MethodSousa, M. B., Isolan, L. R., Oliveira, R. R., Manfro, G. G., & Cordioli, A. V. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0717 · Cited by 110
Moody, T. D., Morfini, F., Cheng, G., Sheen, C., Tadayonnejad, R., Reggente, N., O'Neill, J., & Feusner, J. D. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.192 · Cited by 86
Ferrando, C., & Selai, C. E. (2021) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2021.100684 · Cited by 105
Togao, O., Yoshiura, T., Nakao, T., Nabeyama, M., Sanematsu, H., Nakagawa, A., Noguchi, T., Hiwatashi, A., Yamashita, K., Nagao, E., et al. (2010) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2010.06.011 · Cited by 95
“Previous functional neuroimaging studies have shown functional abnormality in the orbitofrontal cortex (OFC), the anterior cingulate cortex (ACC), the caudate nucleus, and the thalamus (Baxter et al., 1992; Brody et al., 1998; Lucey et al., 1995; Nakao et al., 2005a,b; Nakatani et al., 2005; Rauch et al., 1994; Saxena…”
BackgroundSelf-citationMatsumoto, K., Sutoh, C., Asano, K., Seki, Y., Urao, Y., Yokoo, M., Takanashi, R., Yoshida, T., Tanaka, M., Noguchi, R., et al. (2018) · Journal of Medical Internet Research · doi:10.2196/12091 · Cited by 83
Self-citationAn update on the efficacy of psychological treatments for obsessive-compulsive disorder in adults
Ponniah, K., Magiati, I., & Hollon, S. D. (2013) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2013.02.005 · Cited by 79
“, 2008b) and to Autogenic Training when each was combined with pill-placebo (Nakatani et al., 2005).”
BackgroundMethodInfluentialBokor, G., & Anderson, P. D. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014521996 · Cited by 79
“Fluvoxamine was found to be more effective than placebo but less effective than behavioral therapy in a group of Japanese subjects.(76) Fluvoxamine demonstrated similar efficacy but superior tolerability over clomipramine in a group of 227 patients.”
ResultKim, J. E., Lee, S. W., & Lee, S. J. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.07.036 · Cited by 99
“Notably, the available data suggest that ERP is at least as effective as medication, and may be superior with respect to risks, costs, and enduring benefits (Foa et al., 2005; Nakatani et al., 2005).”
BackgroundPredictors of treatment response to fluvoxamine in obsessive–compulsive disorder: An fMRI study
Sanematsu, H., Nakao, T., Yoshiura, T., Nabeyama, M., Togao, O., Tomita, M., Masuda, Y., Nakatani, E., Nakagawa, A., & Kanba, S. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.08.007 · Cited by 68
“Seven of these participants also participated in our other randomized controlled trial (RCT) study (Nakatani et al., 2005).”
BackgroundSelf-citationChallacombe, F. L., Salkovskis, P. M., Woolgar, M., Wilkinson, E. L., Read, J., & Acheson, R. (2017) · Psychological Medicine · doi:10.1017/s0033291716003573 · Cited by 61
“It has been shown to be effective in a number of studies (Nakatani et al. 2005; Olatunji et al. 2013; Simpson et al. 2013, Öst et al. 2015), with a recent meta-analysis estimating post-treatment effect sizes of 1.”
BackgroundPerinatal Obsessive–Compulsive Disorder: Epidemiology, Phenomenology, Etiology, and Treatment
Hudepohl, N. S., MacLean, J. V., & Osborne, L. M. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01333-4 · Cited by 81
Computerised Cognitive Behaviour Therapy for Obsessive-Compulsive Disorder: A Systematic Review
Tumur, I., Kaltenthaler, E., Ferriter, M., Beverley, C., & Parry, G. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000101497 · Cited by 59
“Although behaviour therapy and selective serotonin reuptake inhibitors are considered the most popular treatment options for OCD, a recent study found behaviour therapy much more effective than medication [”
BackgroundYamanishi, T., Nakaaki, S., Omori, I. M., Hashimoto, N., Shinagawa, Y., Hongo, J., Horikoshi, M., Tohyama, J., Akechi, T., Soma, T., et al. (2009) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2008.07.004 · Cited by 64
“This treatmentmanual has been used successfully in previous outcome trials (Nakatani et al., 2005) The treatments consisted of 45-min sessions one to five times a week for approximately 12 consecutive weeks.”
MethodPredictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder
Hazari, N., Narayanaswamy, J. C., & Arumugham, S. S. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1199960 · Cited by 52
“Four studies found a better response in people with lower baseline severity of illness [19,22,25,26], while three studies found a better response in those with higher baseline severity of illness[20,21,31].”
BackgroundResultKobori, O., Nakazato, M., Yoshinaga, N., Shiraishi, T., Takaoka, K., Nakagawa, A., Iyo, M., & Shimizu, E. (2014) · The Journal of Mental Health Training, Education and Practice · doi:10.1108/jmhtep-10-2013-0033 · Cited by 47
“For example, in a randomized trial, Nakatani et al. (2005) demonstrated that behavioral therapy is highly effective for Japanese patients with OCD.”
Self-citationCurrent status of research on cognitive therapy/cognitive behavior therapy in Japan
Ono, Y., Furukawa, T. A., Shimizu, E., Okamoto, Y., Nakagawa, A., Fujisawa, D., Nakagawa, A., Ishii, T., & Nakajima, S. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02182.x · Cited by 40
“Patients with lower baseline total Y-BOCS, past history of a major depressive episode and absence of cleaning compulsion improved more on fluvoxamine (Table 4).(31,32) There is no other controlled study, but the team at National Sanatorium Kikuchi Keifuen conducted a longitudinal study for obsessive– compulsive disord…”
BackgroundSelf-citationObsessive–compulsive Disorder: Diagnostic and Treatment Issues
Stein, D. J., Denys, D. A. J. P., Gloster, A. T., Hollander, E., Leckman, J. F., Rauch, S. L., & Phillips, K. A. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.007 · Cited by 45
Anholt, G. E., Kempe, P., de Haan, E., van Oppen, P., Cath, D. C., Smit, J. H., & van Balkom, A. J. L. M. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000110058 · Cited by 37
Song, Y., Li, D., Zhang, S., Jin, Z., Zhen, Y., Su, Y., Zhang, M., Lu, L., Xue, X., Luo, J., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114861 · Cited by 31
McDonald, S., Melkonian, M., Karin, E., Dear, B. F., Titov, N., & Wootton, B. M. (2023) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465823000103 · Cited by 31
“Five out of eight studies (Kyrios et al., 2018; Nakatani et al., 2005; Neziroglu et al., 2001; Seol et al., 2016; Wheaton et al., 2021) investigated a variety of psychological, psychosocial, and neuropsychological variables as predictors of treatment.”
BackgroundResultInfluentialHow to grade categories of evidence
Bandelow, B., Zohar, J., Kasper, S. F., & Möller, H. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802456590 · Cited by 33
“Fluvoxamine was and found to be superior to placebo in DBPC studies (Goodman et al. 1989b, 1996; Hohagen et al. 1998; Nakatani et al. 2005) and in clomipramine-controlled trials (Milanfranchi et al.”
BackgroundResultMatsumoto, K., Hamatani, S., Nagai, K., Sutoh, C., Nakagawa, A., & Shimizu, E. (2020) · JMIR Mental Health · doi:10.2196/17157 · Cited by 31
Self-citationMancini, M., Perna, G., Rossi, A., & Petralia, A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003747441 · Cited by 27
“6 Obsessive-compulsive disorder Obsessive-compulsive disorder (OCD) is one of the most common, chronic and disabling anxiety disorders [55], and it is regularly associated with significant comorbidity, especially with depression and personality disorders [56].”
BackgroundPrazeres, A. M., de Souza, W. F., & Fontenelle, L. F. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462006005000046 · Cited by 61
Kotzalidis, G. D., CASALE, A. D., Simmaco, M., Pancheri, L., Brugnoli, R., Paolini, M., Gualtieri, I., Ferracuti, S., Savoja, V., Cuomo, I., et al. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666181026163922 · Cited by 22
Wen, S., Cheng, M., Cheng, M., Yue, J., & Wang, H. (2013) · Behavioral and Brain Functions · doi:10.1186/1744-9081-9-31 · Cited by 19
“imaging studies of OCD patients both before and after treatments using either SSRIs or behavioral therapy suggested that the activity in the OFC, ACC, DLPC, thalamus, and caudate nucleus was decreased by successful treatments [10-12].”
MethodThe development, progress, and current status of cognitive behaviour therapy in Japan
Ishikawa, S., Chen, J., Fujisawa, D., & Tanaka, T. (2019) · Australian Psychologist · doi:10.1111/ap.12450 · Cited by 14
Hamatani, S., Tsuchiyagaito, A., Nihei, M., Hayashi, Y., Yoshida, T., Takahashi, J., Okawa, S., Arai, H., Nagaoka, M., Matsumoto, K., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02841-4 · Cited by 19
“7Cognitive Behavioral Therapy Center, Chiba University Hospital, Chiba, Japan.”
MethodInfluentialPsychotherapy and medication management strategies for obsessive-compulsive disorder
Walsh, K. H., & McDougle (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s13205 · Cited by 17
Skapinakis, P., Caldwell, D. M., Hollingworth, W., Bryden, P. A., Fineberg, N. A., Salkovskis, P. M., Welton, N. J., Baxter, H., Kessler, D. S., Churchill, R. C., et al. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19402 · Cited by 18
Koen, N., & Stein, D. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00038-0 · Cited by 16
Hasanpour, H., Meibodi, R. G., Navi, K., & Asadi, S. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s173388 · Cited by 15
“36,42 45–47 Moreover, forbidden thoughts (sexual/religious/harm-related obsessions) with checking compulsions were associated with better acute medication response, 15,20 but poor long-term outcome and treatment refractoriness were also reported.”
BackgroundYan, J., Cui, L., Wang, M., Cui, Y., & Li, Y. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2103097 · Cited by 17
Wang, Y., Amarnath, A., Miguel, C., Čihařová, M., Lin, J., Zhao, R., Struijs, S. Y., de Wit, L. M., Toffolo, M. B. J., & Cuijpers, P. J. (2024) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2024.152453 · Cited by 11
Mantz, S. C., & Abbott, M. J. (2017) · Behaviour Change · doi:10.1017/bec.2017.6 · Cited by 12
“…and CBT show superior treatment outcomes to pharmacotherapy, with some studies reporting ERP as the preferable treatment (e.g., Foa et al., 2005; Nakatani et al., 2005), and others finding no significant difference between CBT and pharmacotherapy (e.g., Belotto-Silva et al., 2012; Sousa,…”
BackgroundAmeringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 14
McIngvale, E., Kirk, N. P. V., Amspoker, A. B., Stanley, M. A., & Fletcher, T. L. (2019) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.33.1.11 · Cited by 9
“Although medications for OCD are also effective, several clinical trials demonstrate the superiority of ERP to antidepressant medications in reducing OCD symptoms (Foa et al., 2005; Nakatani et al., 2005).”
BackgroundOutcomes of self-help efforts in anxiety disorders
Morgan, A. J., & Jorm, A. F. (2009) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.47 · Cited by 14
Delivery of Exposure and Response Prevention Among Veterans with Obsessive–Compulsive Disorder
Hertz, A. G., Dawson, D. B., Rassu, F. S., Ecker, A. H., Helm, A., Hundt, N. E., & Fletcher, T. L. (2023) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-023-09838-3 · Cited by 8
Thombs, B. D., Grace, S. L., & Ziegelstein, R. C. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.7.1295-a · Cited by 8
Reflections on Relevance: Psychotherapy and Psychosomatics in 2005
Balon, R. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000089221 · Cited by 8
Wang, Y., Miguel, C., Čihařová, M., Amarnath, A., Lin, J., Zhao, R., Toffolo, M. B. J., Harrer, M., Struijs, S. Y., de Wit, L. M., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.197 · Cited by 9
Tubío-Fungueiriño, M., Alemany-Navarro, M., Alonso, P., Arrojo, M., Real, E., Bertolín, S., Menchón, J. M., Carracedo, Á., Fernández‐Prieto, M., & Segalàs, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.063 · Cited by 8
Wheaton, M. G., Schwartz, M. R., Pascucci, O., & Simpson, H. B. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-05 · Cited by 7
A guide to what works for anxiety disorders.
Reavley, N. J., Allen, N. B., Jorm, A. F., Morgan, A. J., Purcell, R., & Beyondblue (2010) · Swinburne figshare (Swinburne University of Technology) · Cited by 8
Smorti, M. (2012) · CINECA IRIS Institutial research information system (University of Pisa) · Cited by 9
Meta-analysis of placebo group dropout in adult antidepressant trials
Li, F., Nasir, M., Olten, B., & Bloch, M. H. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109777 · Cited by 5
Nakatani, E., & Nakagawa, A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000151521 · Cited by 5
Self-citationMaatoug, R., Goff, B. L., Rotgé, J., Jaafari, N., Guillin, O., & Millet, B. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0667-3 · Cited by 4
Jones, M. K., Wootton, B., & Vaccaro, L. (2012) · Case Reports in Psychiatry · doi:10.1155/2012/394603 · Cited by 6
Wheaton, M. G., Hagen, K., Björgvinsson, Þ., Kvale, G., & Hansen, B. K. A. (2024) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2024.100871 · Cited by 7
Shinmei, I., Kanie, A., Kobayashi, Y., Nakayama, N., Takagishi, Y., Iijima, S., Takebayashi, Y., & Horikoshi, M. (2017) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2017.08.002 · Cited by 4
Treatment Manual for Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder
Nakatani, E., Kato, N., & Nakagawa, A. (2016) · Anxiety Disorder Research · doi:10.14389/jsad.7.special_issue_2 · Cited by 3
Self-citationA guide to what works for anxiety
Reavley, N. J., Allen, N., Jorm, A. F., Morgan, A. J., Ryan, S., & Purcell, R. (2013) · Cited by 4
Herpertz, S. C., Jacob, G. A., Külz, A. K., Lieb, K., Schramm, E., Stoffers‐Winterling, J., & Voderholzer, U. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_33 · Cited by 3
Blinding in Psychotherapy Plus Medication Trials
Smith, E. G., & Mathur, A. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.7.1295 · Cited by 3
Williams, M. T., Powers, M. B., & Foa, E. B. (2012) · Wiley eBooks · doi:10.1002/9781118156391.ebcp002013 · Cited by 3
Blakey, S. M., Reuman, L., Jacoby, R. J., & Abramowitz, J. S. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch31 · Cited by 3
Cohen, S., Zantvoord, J., de Boer, T., Mattila, T., van Wingen, G. V., & Denys, D. (2025) · Psychological Medicine · doi:10.1017/s0033291725101335 · Cited by 1
“Nonresponse at the end of the trial was defined as symptom reduction of <35%, a common threshold in OCD trials (Nakatani et al., 2005; Ramak-rishnan et al., 2024).”
Ikemizu, Y., Isobe, Y., Sudo, Y., Ota, J., Chhatkuli, R. B., Sasaki, T., Kurita, K., Yoshida, T., Matsumoto, K., Kuno, M., et al. (2025) · Neuroimage Reports · doi:10.1016/j.ynirp.2025.100275 · Cited by 3
“This manual was developed following earlier studies that demonstrated the efficacy of behavioral therapy for Japanese patients with OCD (Nakatani et al., 2005) and is widely used in clinical practice in Japan as the standard treatment guidelines for OCD, recognized by the Ministry of Health, Labour…”
Self-citationHemanny, C., Iêgo, S., de Sena, E. P., & Dunningham, W. A. (2012) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v11i2.6696 · Cited by 2
Hossein, S., Gharaie, B., & Kazem, A. V. M. (2011) · Advances in Cognitive Science · Cited by 3
Psychological treatmentof obsessive-compulsive disorder: A meta-analysis☆
Alcázar, A. I. R., Sánchez‐Meca, J., Gómez‐Conesa, A., & Marín‐Martínez, F. (2008) · Cited by 1
Sayyah, M., & Rahim, F. (2016) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i1.14528 · Cited by 2
“…patients with OCD Tenneij et al. 2005, Netherlands [60] A randomized, placebo controlled trial Y-BOCS, CGI FLU PBO 12 week 31 outpatients with OCD Nakatani et al. 2005, Japan [61] randomized, double-blind study Y-BOCS score, efficacy FLU PBO 84 week 30 adults with OCD Rufer et al. 2005, Germany…”
MethodMethodological Issues for Clinical Treatment Trials in Obsessive‐Compulsive Disorder
Reghunandanan, S., & Fineberg, N. A. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch8 · Cited by 1
Bednarek, L., Glover, S. J., Ma, X., Pittenger, C., & Pushkarskaya, H. (2022) · medRxiv · doi:10.1101/2022.09.20.22279936 · Cited by 2
“A recent meta-analysis suggested that ERP-based therapies may benefit from augmentation with additional cognitive interventions (Ferrando & Selai, 2021), such as mindfulness (Wilkinson‐Tough et al., 2010), autogenic (Nakatani et al., 2005), or All rights reserved.”
BackgroundCognitive-Behavioral Therapy for Obsessive-Compulsive Disorder
Sassano-Higgins, S. A., Sapp, F., & Noppen, B. L. V. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130207 · Cited by 2
Shareh, H., Banafsheh, G., & Kazem, A. V. M. (2011) · Bushehr University of Medical Sciences Repository (Bushehr University of Medical Sciences) · Cited by 1
Over-Optimism of Cognitive Behavior Therapy for Schizophrenia
Rush, A. J., Shores‐Wilson, K., Katon, W. J., Harpole, L. L., Eh, L., Mt, H., Tang, L., Oishi, S., Langston, C. A., Trivedi, M. H., et al. (2006)
Hemanny, C., Iêgo, S., de Sena, E. P., & Dunningham, W. A. (2012)
Rinawati, F. (2017) · Jurnal Ilmu Kesehatan · doi:10.32831/jik.v4i1.76
Psychological therapies versus pharmacotherapy for obsessive compulsive disorder (OCD)
Veronese, A., Hunot, V., Cipriani, A., Churchill, R. C., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007319.pub2
Safiloo, S., Mehrabi, Y., Asadi, S., & Khodakarim, S. (2021) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017902117010151
Current awareness in human psychopharmacology
(2006) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.729
Turkington, D. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1294a
Psychological therapies versus pharmacotherapy for obsessive compulsive disorder
Veronese, A., Hunot, V., Cipriani, A., Churchill, R. C., & Barbui, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007319
Ponzini, G. T., Hundt, N. E., Christie, I. C., Chen, P. V., Ecker, A. H., Lindsay, J. A., Teng, E. J., Storch, E. A., Myers, U. S., Roussev, M. S., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107445 · Cited by 1
Case 24-2024: A 30-Year-Old Woman with Postpartum Anxiety and Intrusive Thoughts
Meltzer-Brody, S. E., Cohen, L. S., & Miller, E. S. (2024) · New England Journal of Medicine · doi:10.1056/nejmcpc2312735
Research Progress on Etiology and Treatment of Obsessive-Compulsive Disorder
张, 晓. (2024) · Advances in Psychology · doi:10.12677/ap.2024.148543
Kombination von Psychotherapie und Psychopharmaka
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_7
Metadata
- Authors
- Nakatani, E., Nakagawa, A., Nakao, T., Yoshizato, C., Nabeyama, M., Kudo, A., Isomura, K., Kato, N., Yoshioka, K., & Kawamoto, M.
- Affiliations
- Kyushu University (JP)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2005
- Volume
- 74
- Issue
- 5
- Pages
- 269-276
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2033378077
- Cited by
- 102
- References
- 38
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 3 · 2014: 4 · 2013: 8 · 2012: 6
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- obsessive-compulsive disorder, fluvoxamine, behavior therapy, autogenic training, selective serotonin reuptake inhibitors, predictors of treatment response, Japanese patients, treatment efficacy comparison
- MeSH terms
- Adolescent, Adult, Behavior Therapy, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Fluvoxamine, Selective Serotonin Reuptake Inhibitors, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.